50% off Premium Yearly

NYSE:SYK
This summary was created by AI, based on 6 opinions in the last 12 months.
Stryker Corp. (SYK) faces challenges, including the recent cybersecurity incident affecting production and overall weakness in the health sector, but maintains a strong reputation as a leader in medical devices, particularly in orthopedics. Analysts highlight the attractiveness of the stock’s valuation, with expectations of significant earnings growth, forecasting $15 EPS by 2027 at a 20x PE ratio, driven by a 10% topline growth amidst an aging population. With a consistent market share gain from competitors like JNJ and ZBH, Stryker’s focus on robot-assisted surgeries in orthopedics is expected to double in growth over five years. Despite the current struggles in medtech, experts believe holding onto the stock could be beneficial in the long term, given its strong fundamentals and solid track record of acquisitions.
He just bought it. Though healthcare is down 3% YTD, he likes the medical devices space. Medical procedures are coming back. He likes the orthopedic and spine segment of their business, a strong catalyst. Also, supply chains have eased to expand their margins, plus the stock has momentum. Up 20% YTD with more upside ahead.
Stryker makes replacement body parts with several components involved. There is a huge backlog of elective surgeries due to Covid. Also an aging population needs more of these artificial parts so there is lots of growth ahead. Surgeons tend to use the same parts rather than switching to other makes. It has a great balance sheet and may make more acquisitions to grow the business. There may be some cost issues to deal with but this shouldn't be a problem. 70% of its business comes from the U.S. Buy 17 Hold 12 Sell 1